52,586 Shares in Pediatrix Medical Group, Inc. $MD Purchased by Counterpoint Mutual Funds LLC

Key Points

• Counterpoint Mutual Funds LLC purchased 52,586 shares of Pediatrix Medical Group, Inc., valued at approximately $755,000, during the second quarter, increasing institutional ownership to 97.71% of the company's stock.
• Analysts have mixed ratings on Pediatrix Medical Group, with a consensus rating of "Moderate Buy" and varying price targets between $16.50 and $17.00.
• The company's quarterly earnings report indicated an EPS of $0.53, surpassing expectations, despite a 7.1% year-over-year decrease in revenue.

Counterpoint Mutual Funds LLC purchased a new position in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 52,586 shares of the company's stock, valued at approximately $755,000. Counterpoint Mutual Funds LLC owned about 0.06% of Pediatrix Medical Group as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Boston Partners raised its position in shares of Pediatrix Medical Group by 1.3% during the 1st quarter. Boston Partners now owns 1,981,889 shares of the company's stock worth $27,990,000 after purchasing an additional 25,536 shares during the last quarter. Invesco Ltd. raised its position in shares of Pediatrix Medical Group by 9.3% during the 1st quarter. Invesco Ltd. now owns 863,269 shares of the company's stock worth $12,509,000 after purchasing an additional 73,157 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Pediatrix Medical Group by 6.2% during the 1st quarter. Principal Financial Group Inc. now owns 586,190 shares of the company's stock worth $8,494,000 after purchasing an additional 34,266 shares during the last quarter. Bridgeway Capital Management LLC raised its position in shares of Pediatrix Medical Group by 1.7% during the 1st quarter. Bridgeway Capital Management LLC now owns 554,452 shares of the company's stock worth $8,034,000 after purchasing an additional 9,007 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of Pediatrix Medical Group during the 1st quarter worth about $8,024,000. Institutional investors and hedge funds own 97.71% of the company's stock.

Analyst Upgrades and Downgrades

MD has been the subject of several research analyst reports. Leerink Partners upped their price target on shares of Pediatrix Medical Group from $14.50 to $17.00 and gave the stock a "market perform" rating in a research report on Friday, September 5th. UBS Group increased their price objective on shares of Pediatrix Medical Group from $16.00 to $16.50 and gave the company a "neutral" rating in a report on Thursday, August 14th. Wall Street Zen downgraded shares of Pediatrix Medical Group from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 13th. Finally, Zacks Research upgraded shares of Pediatrix Medical Group to a "strong-buy" rating in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $16.79.

Pediatrix Medical Group Stock Performance

NYSE:MD opened at $16.54 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.80 and a current ratio of 1.80. The stock has a market capitalization of $1.44 billion, a P/E ratio of 12.82 and a beta of 1.29. The company has a 50 day moving average price of $15.11 and a 200 day moving average price of $14.24. Pediatrix Medical Group, Inc. has a fifty-two week low of $10.40 and a fifty-two week high of $17.67.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.42 by $0.11. Pediatrix Medical Group had a net margin of 5.66% and a return on equity of 18.94%. The company had revenue of $468.84 million during the quarter, compared to analysts' expectations of $464.37 million. During the same quarter last year, the company posted $0.34 EPS. The firm's revenue was down 7.1% compared to the same quarter last year. Equities research analysts forecast that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pediatrix Medical Group, Inc. (NYSE:MD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.